Equities

Ortin Global Ltd

ORTINGLOBE:NSI

Ortin Global Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)20.86
  • Today's Change-0.34 / -1.60%
  • Shares traded10.53k
  • 1 Year change+6.43%
  • Beta1.9421
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Ortin Global Ltd's revenues fell -64.93% from 60.20m to 21.12m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 936.00k to a larger loss of 80.41m.
Gross margin-315.55%
Net profit margin-1,089.22%
Operating margin-933.98%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

Cash flow information is not available for Ortin Global Ltd.
Cash flow per share-9.82
Price/Cash flow per share--
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Ortin Global Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.